Cargando…
Exploring the Potential of Direct-To-Consumer Genomic Test Data for Predicting Adverse Drug Events
Recent technological advancements in genetic testing and the growing accessibility of public genomic data provide researchers with a unique avenue to approach personalized medicine. This feasibility study examined the potential of direct-to-consumer (DTC) genomic tests (focusing on 23andMe) in resea...
Autores principales: | Zhang, Patrick M., Sarkar, Indra Neil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Informatics Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961769/ https://www.ncbi.nlm.nih.gov/pubmed/29888082 |
Ejemplares similares
-
Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
por: Brown, Joshua D., et al.
Publicado: (2019) -
Low budget analysis of Direct-To-Consumer genomic testing familial data
por: Glusman, Gustavo, et al.
Publicado: (2012) -
Exploring adverse drug events at the class level
por: Winnenburg, Rainer, et al.
Publicado: (2015) -
Potential pitfalls of reproductive direct-to-consumer testing
por: Stanczyk, Frank Z., et al.
Publicado: (2022) -
Adverse Events Related to Direct-To-Consumer Sequential Aligners—A Study of the MAUDE Database
por: Belgal, Priyanka, et al.
Publicado: (2023)